FDA Device Labeling Controls: The Complete 820.45 Guide

FDA device labeling controls are the most prescriptive requirement in the entire Quality Management System Regulation. Section 820.45 of 21 CFR Part 820 names five specific checks, requires two activities to be documented as records, and demands a “detailed description” of the activities that keep labeling under control. It is unusually explicit for a regulation that otherwise defers to ISO 13485.

This guide covers what 820.45 requires, the five accuracy checks, why release is a named record, and the mixup controls that prevent the failure mode this section exists to stop.

What this guide covers

• What FDA device labeling controls require under 820.45
• The five accuracy checks in FDA device labeling controls
• Why FDA device labeling controls name release as a record
• Mixup prevention under FDA device labeling controls
• Automated verification and FDA device labeling controls
• When FDA device labeling controls fail and an error escapes
• FDA device labeling controls for storage and handling
• Frequently asked questions
• Where to go next on FDA device labeling controls

What FDA device labeling controls require under 820.45

820.45 applies in addition to ISO 13485 Clause 7.5.1. It requires documented and maintained procedures that provide a detailed description of the activities ensuring the integrity, inspection, storage and operations for labeling and packaging — during the customary conditions of processing, storage, handling, distribution and, as appropriate, use of the device.

“Detailed description” is the operative phrase. A one-line cross-reference to a work instruction does not meet it, and FDA device labeling controls written as a paragraph will not survive examination.

Note also that “labeling” here takes its meaning from section 201(m) of the Federal Food, Drug, and Cosmetic Act, which supersedes the ISO term labelling and is broader than the label on the device itself.

The five accuracy checks in FDA device labeling controls

Section 820.45(a) requires labeling and packaging to be examined for accuracy prior to release or storage, and names five items the examination must include:

Examine against the medical device file, not the last run

The comparison reference matters more than most FDA device labeling controls procedures make clear. Examine against the approved specification in the medical device file — not against the previous print run.

Comparing against last time propagates an error indefinitely. One mistake, checked against itself at every subsequent run, becomes years of production with nobody detecting it, and the error is only ever found from outside.

Not applicable is a decision, not a blank

Where a check genuinely does not apply — a device with no expiration date, or none requiring special storage — record it as not applicable with the reason. Leaving the field blank is indistinguishable from not performing the check, and only one of those is defensible.

This is exactly what an investigator samples for, because it is countable: five checks, five entries, every time.

Why FDA device labeling controls name release as a record

Section 820.45(b) requires that the release of labeling for use be documented in accordance with Clause 4.2.5 of ISO 13485. FDA singled this out, and the reason is practical.

Release is the control point at which unexamined or superseded labeling can enter production. If release is informal — labeling simply appearing at the line because somebody fetched it — then every downstream control is operating on stock of unknown provenance, and the accuracy examination proves nothing about what was actually used.

The field most often left blank

A release record should capture the labeling item and revision, the device and version it applies to, the accuracy examination reference, the quantity released, who released it and when — and the disposition of the superseded revision.

That last one is the field most often empty and the one most likely to cause harm. Superseded labeling left accessible at the line is the single most common root cause of a mixup. When a revision is released, the previous revision must be quarantined, returned or destroyed, with quantities recorded.

Where superseded stock is deliberately retained for a run-out period, record the authorisation, the expiry of that period, and the physical control keeping it separate.

Mixup prevention under FDA device labeling controls

Section 820.45(c) requires labeling and packaging operations to be established and maintained to prevent mixups, including inspection of the labeling and packaging before use to assure that all devices have correct labeling and packaging as specified in the medical device file — with the results documented per Clause 4.2.5.

Two consequences follow, and both are commonly missed.

The reference is the medical device file. If the specification is not readily available at the line, the inspection cannot be performed as the regulation describes. Uncontrolled printed copies at a workstation are a recurring finding; either date-stamp and expire them, or do not permit them.

The result is a record, including the passes. Recording only failures is not enough. A passing inspection is the evidence that the control operated, and its absence looks identical to the control not being performed at all.

The FDA device labeling controls that actually prevent mixups

• Physical segregation — only one device version’s labeling present at a line at any time.
• Line clearance — documented before every changeover, verified by a second person.
• Issue against order — labeling issued only against a documented production order, in a counted quantity.
• Reconciliation — issued against used, returned and destroyed, at the end of every run.
• Return control — unused labeling returned to controlled storage or destroyed, never left at the line.

Reconciliation is the one that finds problems. An unexplained discrepancy means labeling is either lost or already applied to a device, and both need investigating before further release rather than adjusting the record to balance.

Automated verification and FDA device labeling controls

Vision systems and barcode verification supplement these FDA device labeling controls; they do not replace the requirement. The system itself needs qualification under Clause 7.5.6, and the procedure needs a documented manual fallback for when it is unavailable — an undocumented one is how an unverified run reaches distribution.

When FDA device labeling controls fail and an error escapes

A labeling or packaging error that reaches distribution triggers more than a nonconformity.

It is a complaint source: 820.35(a) requires investigation of any complaint involving possible failure of a device, labeling or packaging to meet specifications. It may be a correction or removal under Part 806 if undertaken to reduce a risk to health. And if the identifier was wrong, it touches your UDI obligations and possibly GUDID.

Treat every mixup as a nonconformity with root cause analysis — including those caught before shipment. Mixups caught internally are the best available signal about the ones that will not be.

FDA device labeling controls for storage and handling

FDA device labeling controls cover storage and handling, not only at the point of application, and this is where a surprising number of failures begin.

Store labeling in a defined, access-restricted location, separated by device and version. Segregate obsolete and superseded stock physically and identify it clearly pending destruction. Apply stock rotation where pre-printed material carries dates. Where the material itself needs environmental control, control it.

Destroy obsolete and surplus labeling so it cannot be reused, with quantity, method and a witness recorded. Labeling recovered from a waste stream and reused is a documented failure mode elsewhere in the industry, and the control costs almost nothing.

Where labeling moves between sites or to a contract packer, control it in transit and confirm receipt against quantity. Reconcile physical stock against records at a defined frequency and investigate discrepancies rather than adjusting the record — unaccounted labeling is either lost or on a device.

Integrity through the device’s real conditions

Labeling must stay legible and affixed through the conditions the device actually meets. If it is sterilised, cleaned, refrigerated, autoclaved or handled with gloves, the labeling has to survive that. Record how integrity was established — by testing, or by qualification of the material and process — rather than assuming it.

Frequently asked questions

Do FDA device labeling controls apply if a contractor prints our labels?

Yes. Labeling is a covered operation, and a manufacturer under 820.3(b) includes those who perform labeling and relabeling. Where a supplier performs it on your behalf, the controls are specified in the contract, the records remain yours, and compliance is audited — records held only by a third party are records you cannot produce.

Does a labeling change need a new device identifier?

Sometimes, and this question should be a mandatory field in your labeling change record rather than a judgement made in passing. A change creating a new version or model requires a new device identifier. Because labeling changes are often treated as minor, this gets skipped — producing devices in the field whose identifier does not distinguish them from a materially different version.

What counts as labeling in FDA device labeling controls?

The FD&C Act 201(m) definition, which supersedes the ISO term and reaches beyond the label on the container to instructions for use and other accompanying material. If you have been scoping labeling controls to the printed label alone, the definition is wider than that.

How does 820.45 relate to Part 801?

They answer different questions. Part 801 governs what the labeling must say. Section 820.45 governs the quality system controls that ensure what it says is correct and reaches the right device. You need both, and meeting one does not evidence the other.

Where to go next on FDA device labeling controls

Labeling controls sit alongside the record supplements in 21 CFR Part 820 section by section, within the wider FDA layer covered in the FDA QMSR guide. Labeling errors are a named complaint trigger — see FDA complaint records for how that limb works.

The full text of 820.45 is on eCFR at 21 CFR Part 820.

Our FDA QMSR Toolkit includes the labeling and packaging control procedure with the detailed description 820.45 requires, an accuracy examination record with a column per mandatory check, the release authorisation record including superseded-stock disposition, the mixup prevention procedure and a reconciliation log. Five checks and two named records are easy requirements to meet and easy ones to be caught missing.